Centre to soon approve Biological E's Corbevax as precaution dose for people above 18 years

New Delhi: The Union health ministry is expected to soon approve Biological E’s Corbevax as a precaution dose for people above 18 years who are double vaccinated with either Covishield or Covaxin, official sources said on Tuesday.

The approval will be based on the recommendations made by the COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI) last week, the sources told PTI.

If approved by the government, this would be the first time a booster dose of a COVID vaccine different from the one used for primary vaccination would be allowed in the country.

“Corbevax will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines for those aged above 18 years enabling use of Corbevax as a heterologous COVID-19 vaccine for precaution dose administration in this age group,” a source said.

More from Health

Excessive energy drink intake can raise stroke and heart risks, doctors warn Planning a baby? Experts explain how antenatal care helps prevent and detect birth defects

This will be in addition to the existing guidelines for homologous precaution dose administration of Covaxin and Covishield vaccines.

India’s first indigenously developed RBD protein subunit vaccine Corbevax is currently being used to inoculate children in the age group of 12 to 14 years under the COVID-19 immunisation programme.

The COVID-19 Working Group (CWG), in its 20 July meeting, reviewed data of the double-blind randomized phase-3 clinical study which evaluated the immunogenicity and safety of booster dose of Corbevax vaccine when administered to COVID-19-negative adult volunteers of age 18-80 years previously vaccinated with two doses of either Covishield or Covaxin.

“Following the examination of the data, the CWG observed that Corbevax vaccine can induce significant increase in antibody titers when given to those who have received either Covaxin or Covishield, which is likely to be protective as per the neutralization data also,” the source said.

Quick Reads

View All

Decades of nuclear tests linked to 4 mn premature deaths globally, report says

Abu Dhabi launches new blood test that detects over 70 hard-to-find cancers in early stages

The Drugs Controller General of India (DCGI) on 4 June approved Corbevax as a precaution dose for those aged 18 and above.

India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from 10 January.

The country began inoculating children aged 12-14 from 16 March and also removed the comorbidity clause making all people aged above 60 eligible for the precaution dose of COVID vaccine.

India on April 10 began administering precaution doses of COVID-19 vaccines to all aged above 18 years.

Read all the Latest News, Trending News, Cricket News, Bollywood News,
India News and Entertainment News here. Follow us on Facebook, Twitter and Instagram.